GLP-1 drugs cut heart and kidney risks in type 1 diabetes study
In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated with lower risks of major cardiovascular events and end-stage kidney disease…